Drug Profile
Companion diagnostic for MTX5 and MTX3-targeting ADCs - Oncomatryx
Latest Information Update: 12 Sep 2023
Price :
$50
*
At a glance
- Originator Oncomatryx
- Class Diagnostic agents; Monoclonal antibodies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 12 Sep 2023 Preclinical trials in Cancer (Diagnosis) in Spain (unspecified route) (Oncomatryx pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Cancer(Diagnosis) in Spain
- 27 Jul 2016 Preclinical trials in Cancer (Diagnosis) in Spain (unspecified route)